C4X Discovery Holdings has now withdrawn from the platform.
In the auction that closed on 12th February 2026, 97,191 shares traded at 4.5 pence per share.
Please direct any queries to dealing@assetmatch.com or Tel. 020 7248 2788
Interested in C4X Discovery Holdings Ltd?
Register or log in to participate, create a watchlist, or set reminder
C4X Discovery Holdings Ltd (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. Our internal portfolio of discovery programmes is advancing towards clinical trials with one programme in the pre-clinical candidate selection stage. We have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.
C4X Discovery Holdings Auction Details
The Ordinary Shares of C4X Discovery Holdings Ltd were admitted to trading on Asset Match on 26 April 2024 at a price of 12 pence per share (being the last traded price on AIM).
Auctions are to be held quarterly and close at 4pm on the second Thursday of each month (unless stated otherwise).
The tick size for this company is 0.25 pence per share.
Please read the auction instructions section below for more information on how to participate.
C4X Discovery Holdings Trading History (last 10)
Buying and Selling Shares via Asset Match Private Market
To buy or sell shares in this company through the Asset Match Private Market, you will need to use a stockbroker.
If you already have an existing relationship with a UK broker on our approved broker list, you should be able to place an order to participate directly through them.
If you do not currently have a broker, please contact us and we will provide guidance on suitable options.
If you require assistance or have any questions about participating, please contact us:
📞 +44 (0)20 7248 2788
Fees
When buying or selling shares, an Asset Match levy of 3% applies, with a minimum charge of £20 per trade (additional broker fees may also apply).
For more information on how the auction process works, please click here.
David Lawrence Interim Non-Executive Chairman
David joined C4XD in December 2024. He is currently a Non-Executive Director at EnteroBiotix, a UK private, clinical-stage microbiome company, and Glen Clova Scientific, a UK private biotech creating a new class of active biologics. He began his career at GSK and has held senior and executive roles at leading companies such as Chiron Vaccines which was acquired by Novartis and Acambis which was acquired by Sanofi and Valneva, where he led its US IPO. David also co-founded Synpromics, a synthetic biology company, where he recruited the senior management team and the Board; Synpromics was acquired by Ask Bio in 2019.
Emma Blaney PhD Interim CEO
Emma has been Interim CEO since January 2025 and leads the business with responsibility for defining and implementing strategy, ensuring its continued growth focused on the development of new and innovative immuno-inflammatory therapeutics. As a trained medicinal chemist, Emma joined C4XD in 2014 as a Senior Programme Manager and has gained more than 18 years’ experience working on Drug Discovery programmes within the Pharmaceutical sector. She brings extensive project management experience to the Executive Team with a particular focus on outsourcing management and collaborations. Previously she was a Section Head at Peakdale Molecular leading multiple projects for pharmaceuticals clients and a Medicinal Chemistry Team Leader at GSK within the Neurology and Gastrointestinal Department. Emma has a PhD in Synthetic Organic Chemistry from the University of Leeds, and a first-class Chemistry and Pharmacology degree from the University of Liverpool.
Julian Lord Interim Chief Financial Officer
Julian has 20 years’ experience in the life sciences industry and joined C4XD in December 2024. He is also CFO at Edinburgh Molecular Imaging, a clinical stage company developing a c-Met targeted radioligand therapy. Julian was previously CFO at Caldan Therapeutics and Group Financial Controller at Mereo BioPharma Group, working on establishing and growing the finance function and successful listings on AIM and Nasdaq. Prior to Mereo, he was Financial Controller at Immune Targeting Systems (ITS) Ltd from 2010 through to its merger with Vaxin Inc in 2015. Julian holds a BA (Hons) from Durham University and is a qualified management accountant (ACMA, CGMA).
Nick Ray PhD Chief Scientific Officer
Nick oversees the C4XD Drug Discovery portfolio from target selection through to pre-clinical candidate generation and partnering alongside Dr. Clare Murray, SVP Drug Discovery. Nick also leads the medicinal chemistry, structural analysis and computational chemistry/cheminformatics teams and together, with our CTO Dr Charles Blundell, is leading the continued development of our conformational analysis technology, 4Sight.
Nick joined C4XD in 2016 and has more than 30 years’ experience leading key programmes at large multi-national companies including Rhône-Poulenc, Celltech and Argenta/Charles River, in the therapeutic areas of oncology, respiratory diseases, inflammation, CNS, pain and metabolic diseases. Eight of these programmes have progressed into the clinic to date. As head of the chemistry department at Charles River’s Harlow U.K. site, Nick was responsible for more than 70 chemists, fostering both the importance of strong medicinal and synthetic chemistry skills and championing professional development for his team, winning the Royal Society of Chemistry Retrosynthesis competition in 2015. He is a named inventor on over 75 patents and patent applications and has published 21 papers and presentation abstracts. Nick holds a PhD in organic chemistry from the University of Birmingham, UK.
Harmesh Suniara Non-Execuive Director
Harmesh has over 15 years’ experience of working in investment management, with a particular focus on UK small and mid-cap equities including the technology and life sciences sectors. He brings a wealth of expertise in active engagement with companies that Lombard Odier has invested in. He has worked as a Portfolio Manager at Lombard Odier 1798 Volantis since 2017, and prior to this he was an Investment Manager at Henderson Volantis Capital and Gartmore Investment Management. Harmesh graduated in Physics from the University of Cambridge. Lombard Odier 1798 Volantis is a major shareholder in C4X Discovery.
Richard Jones Non-Executive Director
Richard Jones is an experienced healthcare and life sciences Director. He was most recently CFO of Medica Group, a PE backed international tele-medicine business which was taken private in a £270m deal by IK partners from the UK main market; and is currently SID and Chair of the Audit Committee at Alliance Pharma PLC, an AIM listed consumer healthcare company.
Richard previously gained extensive experience in the healthcare sector as CFO at UK AIM Listed companies Mereo BioPharma Group PLC and Shield Therapeutics PLC. At Mereo, he had a leading role in the merger with US listed OncoMed Pharmaceuticals, Inc and its subsequent dual listing on Nasdaq in 2019. At Shield, he established the finance operations and guided the company through several private financing rounds and its 2016 IPO. Prior to his CFO roles, Richard held senior investment banking positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC.
Shilina Roman SVP Drug Discovery
Shilina Roman is SVP Drug Discovery and a member of the Executive Team. Shilina manages the biology team and oversees all aspects of drug discovery across the drug discovery portfolio. Prior to joining C4XD, Shilina was Senior Director, Head of Biology and Translational Medicine at Eliem Therapeutics, leading the biology and scientific strategy on project teams. Having started as a research scientist at GSK and Argenta Discovery, Shilina has significant experience in the drug discovery process from target identification through to phase 2 clinical trials, she held senior management roles at Charles River Laboratories and Eliem Therapeutics. Shilina has a B.Sc (Hons) in Biochemistry and Pharmacology from Kings College, London and a Diploma in Advanced Pharmacology from the British Pharmacological Society, with more than 15 published papers.